On August 27, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, reported that it participated in the Virtual Investor "Why Now" on-demand conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes now is a pivotal time for Ernexa. The pitch discusses the Company’s planned transition into a clinical-stage biotechnology company, with lead candidate ERNA-101 advancing toward a planned Investigational New Drug (IND) submission and, importantly, the start of its first-in-human Phase 1 clinical study.
The discussion also highlights ERNA-101’s differentiated, off-the-shelf iMSC platform, encouraging preclinical results in ovarian cancer models and the Company’s continued execution across manufacturing, regulatory and clinical activities supporting its advancement into the clinic.
JTC Team and Virtual Investor Co. are paid consultants to Ernexa Therapeutics. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Ernexa Therapeutics. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and filings on the Company.
(Press release, Ernexa Therapeutics, AUG 27, 2026, View Source [SID1234670403])